Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05647343 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers
A Phase 1 study of Adverse Effect of Drugs and Medicaments in Therapeutic Use, sponsored by Atlas Molecular Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT05647343: Completed Phase 1 study of Adverse Effect of Drugs and Medicaments in Therapeutic Use, sponsored by Atlas Molecular Pharma.
NCT05647343 is a Phase 1 study of Adverse Effect of Drugs and Medicaments in Therapeutic Use that has completed, run by Atlas Molecular Pharma. The registered enrollment target is 42 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05647343, a Phase 1 study of Adverse Effect of Drugs and Medicaments in Therapeutic Use, has completed, sponsored by Atlas Molecular Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to assess the safety, tolerability and pharmacokinetics of ATL-001 (ciclopirox olamine) in healthy volunteers
Primary Outcome
Incidence of adverse events (AEs) and of clinically relevant changes in vital signs values, electrocardiogram (ECG) data, physical examination and laboratory safety data for four different doses of ATL-001
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Ciclopirox Olamine Oral
Study Locations (1)
New Jersey
- Hassman Research Institute, LLC - Berlin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-03-31 |
| Est. Completion | 2024-04-08 |
| Phase | Phase 1 |
What the finished NCT05647343 record still lists
NCT05647343 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower).
The record links to 1 condition, with Adverse Effect of Drugs and Medicaments in Therapeutic Use appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05647343 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT05647343 about?
NCT05647343 is a clinical study titled "Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers". The goal of this clinical trial is to assess the safety, tolerability and pharmacokinetics of ATL-001 (ciclopirox olamine) in healthy volunteers
What is the current status of trial NCT05647343?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2023-03-31. Estimated completion is 2024-04-08.
What conditions does trial NCT05647343 study?
This clinical trial studies the following conditions: Adverse Effect of Drugs and Medicaments in Therapeutic Use.
What interventions are being tested in trial NCT05647343?
The interventions under investigation include: Placebo (OTHER), Ciclopirox Olamine Oral (DRUG).
Who is sponsoring clinical trial NCT05647343?
This trial is sponsored by Atlas Molecular Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05647343 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05647343's enrollment target sits among peer trials
42 1105th of 2000 higher than 876 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI